查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年美国和欧洲细胞和基因治疗製造服务市场预测 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）、最终用户和国家进行区域分析
市场调查报告书
商品编码
1347187

到 2030 年美国和欧洲细胞和基因治疗製造服务市场预测 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）、最终用户和国家进行区域分析

US and Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User, and Country
出版日期: | 出版商: The Insight Partners | 英文 147 Pages | 订单完成后即时交付

价格

2022年，美国和欧洲的细胞和基因治疗製造服务市场价值为47.735亿美元，预计到2030年将达到168.691亿美元；预计2022年至2030年復合年增长率为17.1%。

细胞和基因疗法批准数量的增加以及外包细胞和基因疗法製造服务的日益普及是影响美国和欧洲细胞和基因疗法製造服务市场规模增长的主要因素。然而，细胞和基因治疗製造服务的高初始成本阻碍了美国和欧洲细胞和基因治疗製造服务市场的增长。

细胞和基因治疗（CGT）项目正在从研发快速推进到临床试验和商业批准。建立稳健、可重复且可持续的流程有助于加速开发，避免与製造转移相关的延误。此外，细胞和基因疗法包括下一代生命增强和治疗疗法。随着疗法获得新的批准，对细胞和基因疗法製造服务领域熟练专业人员的需求将会上升。

外包细胞和基因治疗製造越来越受欢迎

细胞和基因疗法的製造是一个复杂的过程，这使得正确执行和监督操作至关重要。细胞和基因治疗製造商了解生物和工艺工程的合格人员数量有限。此外，对于经验丰富的团队来说，使用手动和开放製造方法来管理首次临床试验的尝试，然后构建更适合商业的流程可能会很棘手。因此，这些企业选择与合同开发和製造组织（CDMO）合作来加速其临床研究和商业化进程。 CDMO 以合同形式向细胞和基因治疗公司提供产品开发、製造、临床试验支持和商业化服务。与 CDMO 合作可以帮助细胞和基因治疗製造商实现可扩展性、加快上市速度、无需管理成本即可获得技术专业知识以及成本效率。

2020年1月，Deerfield Management Company和MLP Ventures的发现实验室在美国宾夕法尼亚州建立了突破性药物中心。这个新的 CDMO 设施将占据 Discovery Labs 园区 40% 以上的面积。在该空间中，CDMO 将安装 10 个质粒套件； 20 个病毒载体套件； 36 个通用细胞处理套件；以及 20 个现行良好生产规范 (cGMP) 测试、工艺开发和细胞库套件。 Deerfield Management Company 和 Discovery Labs 已投资 11 亿美元建设技术开发设施，以支持细胞和基因疗法的生产。此外，2020年3月，Fujifilm Cellular Dynamics（FCDI）投资2100万美元建设符合cGMP的生产设施，该设施将用于製造FCDI使用诱导多能干细胞（iPSC）的再生医学疗法的管道并提供CDMO服务用于生产iPSC 和iPSC 衍生的分化细胞。 2022年4月，ThermoGenesis在美国加利福尼亚州建立了CDMO设施，利用其在T细胞受体（TCR）、嵌合抗原受体-T细胞（CAR-T细胞）、肿瘤等领域的专业知识，为细胞和基因治疗製造商提供CDMO服务。 -浸润白细胞（TIL）、iPSC、自然杀伤细胞（NK）和间充质干细胞（MSC）製造。

事实证明，将细胞和基因治疗製造外包给 CDMO 对于製造商来说具有成本效益。此外，他们还可以获得 CDMO 技术先进的基础设施和专业知识。 CDMO 采用适当的、映射的流程来製造细胞和基因疗法。因此，越来越倾向于将不断增长的细胞和基因治疗製造外包给 CDMO，推动了美国和欧洲细胞和基因治疗製造服务市场的增长。

細項分析

基于最终用户的见解

根据最终用户，市场分为製药和生物技术公司以及合同研究组织（CRO）。製药和生物技术公司细分市场到 2022 年将占据更大的市场份额，预计该细分市场在预测期内的市场复合年增长率将更高。美国主要製药和生物技术公司致力于提供用于治疗急性和罕见疾病的 CGT，这些疾病对传统方法没有反应，其中包括 ElevateBio 和 Discovery Labs。这些公司致力于创建药品合同开发和製造组织 (CDMO) 的全新分支。他们将通过投资资本利得税相互竞争，并与少数大型服务公司竞争。上述因素将产生有影响力的细分市场增长，从而主导 2022-2030 年美国和欧洲细胞和基因治疗製造服务市场的增长。

适应症见解

根据迹象，美国和欧洲的细胞和基因治疗製造服务市场分为癌症、骨科和其他。到 2022 年，癌症细分市场占据最大市场份额，预计该细分市场在预测期内将以最高复合年增长率增长。

类型洞察

根据类型，细胞和基因治疗製造服务市场分为细胞治疗和基因治疗。细胞疗法分为自体细胞疗法和同种异体细胞疗法。此外，基因治疗分为病毒载体和非病毒载体。细胞疗法通过恢復或改变某些细胞群或提供细胞在体内进行治疗来帮助治疗紊乱和疾病。细胞疗法在引入患者之前在体外形成或修饰细胞。细胞可以来自患者（自体细胞）或供体（同种异体细胞）。细胞疗法领域的增长归因于进入市场的产品数量不断增加、细胞疗法在治疗自身免疫性疾病、癌症和传染病方面的潜在应用以及大量正在进行的临床试验。超过 360 项专注于 CAR-T 细胞疗法和其他细胞疗法的临床试验正在研究中，以解释这些疗法治疗各种疾病适应症的潜力。因此，预计未来几年对先进治疗製造服务的需求将会增加。

在准备美国和欧洲细胞和基因治疗製造服务市场报告时提到的一些主要一手和二手来源是美国国立卫生研究院基金会、国家卫生服务机构以及药品和保健产品监管局。

目录

第 1 章：简介

  • 研究范围
  • Insight Partners 研究报告指南
  • 市场区隔
    • 美国和欧洲细胞和基因治疗製造服务市场 - 按类型
    • 美国和欧洲细胞和基因治疗製造服务市场 - 按适应症分类
    • 美国和欧洲细胞和基因治疗製造服务市场 - 按应用
    • 美国和欧洲细胞和基因治疗製造服务市场 - 按最终用户
    • 美国和欧洲细胞和基因治疗製造服务市场 - 按国家和地区划分

第 2 章：美国和欧洲细胞和基因治疗製造服务市场 - 要点

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：美国和欧洲细胞和基因治疗製造服务市场 - 市场格局

  • 概述
  • PEST分析
    • 美国PEST分析
    • 欧洲PEST分析
  • 专家意见

第 5 章：美国和欧洲细胞和基因治疗製造服务市场 - 主要市场动态

  • 市场驱动因素
    • 细胞和基因疗法批准数量的增加
    • 外包细胞和基因治疗製造越来越受欢迎
  • 市场限制
    • 细胞和基因疗法製造成本高昂
  • 市场机会
    • 公司的战略倡议
  • 未来的趋势
    • 细胞和基因治疗製造服务的自动化
  • 影响分析

第 6 章：美国和欧洲细胞和基因治疗製造服务市场 - 国家和地区分析

  • 美国和欧洲细胞和基因治疗製造服务市场收入预测与分析
  • 关键参与者的市场定位

第 7 章：美国和欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按类型

  • 概述
  • 美国和欧洲细胞和基因治疗製造服务市场收入份额，按类型 2022 年和 2030 年 (%)
  • 细胞疗法
  • 基因治疗

第 8 章：美国和欧洲细胞和基因治疗製造服务市场分析和 2030 年预测 - 按指标

  • 概述
  • 美国和欧洲细胞和基因治疗製造服务市场，按适应症划分 2022 年和 2030 年 (%)
  • 癌症
  • 骨科
  • 其他的

第 9 章：美国和欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 -按应用

  • 概述
  • 2022 年和 2030 年美国和欧洲细胞和基因治疗製造服务市场收入份额（按应用划分）
  • 临床製造
  • 商业製造

第 10 章：美国和欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 2022 年和 2030 年美国和欧洲细胞和基因治疗製造服务市场收入份额（按最终用户划分）（%）
  • 製药和生物技术公司
  • 合同研究组织 (CRO)

第 11 章：美国和欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 国家和地区分析

    • 概述
      • 美国：2020-2030 年美国和欧洲细胞和基因治疗製造服务市场（按类型）
      • 美国：美国和欧洲细胞和基因治疗製造服务市场，按适应症划分，2020-2030 年
      • 美国：2020-2030 年美国和欧洲细胞和基因治疗製造服务市场（按应用）
      • 美国：美国和欧洲细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
  • 欧洲：美国和欧洲细胞和基因治疗製造服务市场
    • 概述
    • 欧洲：2020-2030 年美国和欧洲细胞和基因治疗製造服务市场（按类型）
      • 欧洲：美国和欧洲细胞和基因治疗製造服务市场，按 Cell Therapy 划分，2020-2030 年
      • 欧洲：美国和欧洲细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 欧洲：美国和欧洲细胞和基因治疗製造服务市场，按适应症划分，2020-2030 年
    • 欧洲：2020-2030 年美国和欧洲细胞和基因治疗製造服务市场（按应用）
    • 欧洲：美国和欧洲细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 欧洲：美国和欧洲细胞和基因治疗製造服务市场，按国家/地区划分，2022 年和 2030 年（%）

第 12 章：美国和欧洲细胞和基因治疗製造服务市场 - 行业格局

  • 概述
  • 美国和欧洲细胞和基因治疗製造服务市场的增长策略
  • 有机增长策略
    • 概述
  • 无机增长策略
    • 概述

第 13 章：公司简介

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd?
  • Catalent Inc
  • Takara Bio Inc
  • Nikon Corp
  • FUJIFILM Holdings Corp
  • National Resilience Inc
  • Oxford BioMedica Plc

第 14 章：附录

  • 关于 Insight Partners
  • 专业术语
Product Code: TIPRE00029984

The US and Europe cell and gene therapy manufacturing services market was valued at US$ 4,773.5 million in 2022 and is projected to reach US$ 16,869.1 million by 2030; it is estimated to register a CAGR of 17.1% from 2022 to 2030.

An increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing services are among the major contributing factors influencing the growth of US and Europe cell and gene therapy manufacturing services market size. However, high initial cost of cell and gene therapy manufacturing services hinders the growth of the US and Europe cell and gene therapy manufacturing services market.

Cell and gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing a robust, repeatable, and sustainable process help to accelerate the development, avoiding manufacturing transfer-related delays. Additionally, cell and gene therapy comprises the next generation of life-enhancing and curative therapies. With therapies experiencing new approvals, the demand for skilled professionals in cell and gene therapy manufacturing services will rise.

Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers.

In January 2020, Deerfield Management Company and The Discovery Labs of MLP Ventures established the Center for Breakthrough Medicines in Pennsylvania, US. This new CDMO facility would occupy more than 40% of the campus created by The Discovery Labs. In that space, the CDMO would install 10 plasmid suites; 20 viral vector suites; 36 universal cell processing suites; and 20 current good manufacturing practice (cGMP) testing, process development, and cell banking suites. Deerfield Management Company and The Discovery Labs have invested US$ 1.1 billion to raise a technologically developed facility to support the manufacturing of cell and gene therapies. Further, in March 2020, Fujifilm Cellular Dynamics (FCDI) invested US$ 21 million in the cGMP-compliant production facility, which would be used for manufacturing FCDI's pipeline of regenerative medicine therapies using induced pluripotent stem cells (iPSCs) and to provide CDMO services for production of iPSCs and iPSC-derived differentiated cells. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing.

Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Moreover, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the US and Europe cell and gene therapy manufacturing services market growth.

Segmental Analysis

End User-Based Insights

Based on end user, the market is segmented into pharmaceutical and biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment held a larger share of the market in 2022 and the same segment is anticipated to register a higher CAGR in the market during the forecast period. Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs. The aforementioned factors will be responsible for influential segmental growth thereby dominating the US and Europe cell and gene therapy manufacturing services market growth during 2022-2030.

Indication Insights

Based on indication, the US and Europe cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period.

Type Insights

Based on type, the cell and gene therapy manufacturing services market is segmented cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. Therefore, the demand for advanced therapy manufacturing services is anticipated to increase in the coming years.

A few of the major primary and secondary sources referred to while preparing the report on the US and Europe cell and gene therapy manufacturing services market are the Foundation for the National Institutes of Health, National Health Services, and Medicines and Healthcare Products Regulatory Agency.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US and Europe cell and gene therapy manufacturing services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US and Europe cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the US and Europe cell and gene therapy manufacturing services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Type
    • 1.3.2 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Indication
    • 1.3.3 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Application
    • 1.3.4 US and Europe Cell and Gene Therapy Manufacturing Services Market - by End User
    • 1.3.5 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Country & Region

2. US and Europe Cell and Gene Therapy Manufacturing Services Market - Key Takeaways

3. Research Methodology

  • 3.2 Coverage
  • 3.3 Secondary Research
  • 3.4 Primary Research

4. US and Europe Cell and Gene Therapy Manufacturing Services Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US PEST Analysis
    • 4.2.2 Europe PEST Analysis
  • 4.3 Expert's Opinion

5. US and Europe Cell and Gene Therapy Manufacturing Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.5 Impact Analysis

6. US and Europe Cell and Gene Therapy Manufacturing Services Market - Country & Regional Analysis

  • 6.1 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • 7.3 Cell Therapy
    • 7.3.1 Overview
    • 7.3.2 Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.1 Autologous
        • 7.3.2.1.1 Overview
        • 7.3.2.1.2 Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.2 Allogenic
        • 7.3.2.2.1 Overview
        • 7.3.2.2.2 Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Viral Vector
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.2 Non-Viral Vector
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. US and Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

  • 8.1 Overview
  • 8.2 US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • 8.3 Cancer
    • 8.3.1 Overview
    • 8.3.2 Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Orthopedics
    • 8.4.1 Overview
    • 8.4.2 Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

  • 9.1 Overview
  • 9.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • 9.4 Clinical Manufacturing
    • 9.4.1 Overview
    • 9.4.2 Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Commercial Manufacturing
    • 9.5.1 Overview
    • 9.5.2 Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

  • 10.1 Overview
  • 10.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 10.4 Pharmaceutical and Biotechnology Companies
    • 10.4.1 Overview
    • 10.4.2 Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Contract Research Organizations (CROs)
    • 10.5.1 Overview
    • 10.5.2 Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country & Regional Analysis

  • 11.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.1.1 Overview
    • 11.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 11.1.2.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.1.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.2.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 11.1.2.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 11.1.2.3 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 11.1.2.4 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market
    • 11.2.1 Overview
    • 11.2.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.2.3 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.2.3.1 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.2.3.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.2.4 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.2.5 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.2.6 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.2.7 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
      • 11.2.7.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.1 Overview
        • 11.2.7.1.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.3 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.1.3.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.3.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.4 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.1.5 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.1.6 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.1 Overview
        • 11.2.7.2.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.3 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.2.3.1 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.3.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.4 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.2.5 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.2.6 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.1 Overview
        • 11.2.7.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.3.3.1 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.4 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.3.5 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.3.6 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.1 Overview
        • 11.2.7.4.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.3 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.4.3.1 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.3.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.4.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.4.6 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.1 Overview
        • 11.2.7.5.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.3 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.5.3.1 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.3.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.4 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.5.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.5.6 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.1 Overview
        • 11.2.7.6.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.6.3.1 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.3.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.6.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.6.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. US and Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Thermo Fisher Scientific Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck KGaA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Charles River Laboratories International Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Lonza Group AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi AppTec Co Ltd?
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Takara Bio Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Nikon Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 FUJIFILM Holdings Corp
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 National Resilience Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Oxford BioMedica Plc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 2. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 47. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Recent Organic Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Table 50. Recent Inorganic Growth Strategies in the US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Table 51. Glossary of Terms

List Of Figures

  • Figure 1. US and Europe Cell and Gene Therapy Manufacturing Services Market Segmentation
  • Figure 2. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Region
  • Figure 3. US and Europe Cell and Gene Therapy Manufacturing Services Market Overview
  • Figure 4. Cell Therapy Segment Held Largest Share of Type Segment in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Figure 5. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country & Region (US$ Million)
  • Figure 6. US and Europe Cell and Gene Therapy Manufacturing Services Market - Leading Country Markets (US$ Million)
  • Figure 7. US and Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape
  • Figure 8. US: PEST Analysis
  • Figure 9. Europe: PEST Analysis
  • Figure 10. Experts' Opinion
  • Figure 11. US and Europe Cell and Gene Therapy Manufacturing Services Market: Key Industry Dynamics
  • Figure 12. US and Europe Cell and Gene Therapy Manufacturing Services Market: Impact Analysis of Drivers and Restraints
  • Figure 13. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue Forecast and Analysis - 2021-2030
  • Figure 14. Market Positioning of Key Players in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Figure 15. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 16. Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application 2022 & 2030 (%)
  • Figure 23. Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Others: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 27. Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 30. Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. United States: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 33. US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 35. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
  • Figure 37. Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 38. UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 39. France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 41. Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 42. Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 43. Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market